Group 1 - WuXi AppTec plans to adjust the maximum repurchase price of its A-shares from 90.72 yuan to 114.15 yuan per share, while the other details of the repurchase plan remain unchanged. The current closing price is 98.69 yuan per share [1] Group 2 - Time Space Technology has terminated the planning of a change in control due to the inability to reach an agreement on core terms with its controlling shareholder. The termination will not have a significant adverse impact on the company's operating performance and financial status [2] Group 3 - Dong'an Power's indirect controlling shareholder has changed to China Changan Automobile following the division of the Equipment Group approved by the State Council. China Changan now indirectly holds 50.93% of Dong'an Power's total shares [3] Group 4 - Changchun High-tech's subsidiary has received FDA approval for its innovative drug, Amlodipine Besylate Oral Solution Lyophilized Powder, aimed at treating hypertension in children over 6 years old and adults with swallowing difficulties [4] Group 5 - Wantong Intelligent Control has signed an exclusive authorization agreement with Shanghai Shenming Aosi Semiconductor Technology for the production and sale of boards based on the Fellow 1 model chip in the embodied intelligence field, which is expected to positively impact the company's future development [5] Group 6 - Hunan Tianyan's indirect controlling shareholder has changed to China Changan Automobile after the division of the Equipment Group. China Changan now indirectly holds 37.25% of Hunan Tianyan's shares [6] Group 7 - Zhixiang Jintai has received approval for clinical trials of its product, Silevimi Monoclonal Antibody Injection, aimed at passive immunity for suspected rabies virus exposure in children and adolescents [7] Group 8 - Liyuan Technology's actual controller has been sentenced to one year in prison for the crime of disclosing important information in violation of regulations, but this will not significantly impact the company's operations [8] Group 9 - Huqin Technology plans to acquire 6% of Crystal Integrated's shares for 2.393 billion yuan, with the aim of deepening resource integration and strategic investment [10] Group 10 - Lakala's major shareholder, Lenovo Holdings, has reduced its stake by 5.3596 million shares, bringing its ownership down to 25.86%, which will not affect the company's governance structure [11]

药明康德(603259.SH)公告称，公司预计2025年持续经营业务收入重回双位数增长，增速从10-15%上调 至13-17%。公司预计全年整体收入从人民币415-430亿元上调至人民币425-435亿元。公司将持续聚焦 CRDMO核心业务，持续提高生产经营效率。2025年上半年，为加大股东回报，公司首次进行特别分红 约人民币10亿元（该分红已于2025年5月完成）；同时，为进一步提高分红频次，增强投资者回报水平 和获得感，公司董事会已审批通过《关于公司2025年中期利润分配方案的议案》，拟共计派发现金红利 约人民币10亿元。 ...

海外业务的高韧性成为业绩增长的重要驱动力。今年上半年，公司持续经营收入204.1亿元，海外客户 收入占比约85%。其中，来自美国客户的收入有140.3亿元，同比增长38.4%；来自欧洲客户的收入有 23.3亿元，同比增长9.2%。 信达证券研报指出，从2024年生物安全法案到2025年中美关税冲突，市场对于地缘政治风险的担忧已经 充分演绎，2025年H1公司来自美国客户的业务增速依然强劲，再次打消市场疑虑，全球化趋势难以抵 挡，公司在全球产业链中地位稳健。 细分业务中，TIDES（寡核苷酸和多肽）表现尤为亮眼。上半年，药明康德TIDES业务保持高速增长， 成为拉动业绩的关键因素之一。其业务收入50.3亿元，同比增长1.42倍，约占公司整体收入的24%。 7月29日，药明康德港股涨超11%，带动今日港股CRO板块逆势走强，泰格医药涨超9%，昭衍新药涨超 9%，康龙化成涨超7%。板块集体上扬的背后，是药明康德前一日发布的半年报数据为市场注入强心 针。 前一日晚间，药明康德公布2025年半年报。药明康德上半年营业收入208亿元，同比增长20.6%。归母 净利润85.61亿元，同比增长101.9%。今年上半年，公司持 ...

Core Viewpoint - WuXi AppTec (2359.HK) reported better-than-expected performance in the first half of the year, with revenue reaching 20.8 billion yuan, a year-on-year increase of 20.6% [1] - Net profit increased by 102% year-on-year to 8.6 billion yuan, while recurring net profit, excluding a one-time gain of 3.3 billion yuan from the sale of WuXi AppTec's stake, grew by 26.5% to 5.9 billion yuan [1] Financial Performance - Revenue for the first half of the year was 20.8 billion yuan, reflecting a 20.6% year-on-year growth [1] - Net profit surged by 102% year-on-year to 8.6 billion yuan [1] - Recurring net profit increased by 26.5% to 5.9 billion yuan when excluding one-time gains [1] Guidance and Projections - Management raised the full-year revenue guidance by 2% to a range of 42.5 billion to 43.5 billion yuan [1] - Free cash flow guidance was increased by 22% to a range of 5 billion to 6 billion yuan [1] - Capital expenditure budget remains unchanged at 7 billion to 8 billion yuan [1] Business Segments - TIDES business revenue grew by 142% year-on-year to 5 billion yuan, driven by GLP-1 raw material drugs, exceeding the annual growth target of 60% [1] - The second quarter gross margin reached a new high of 46.9%, attributed to improved production efficiency in the chemical business and an increase in later-stage projects [1] - However, only 8 new commercialization and phase III projects were added in the first half, and the China business experienced a year-on-year decline of 5% [1] Analyst Rating - The firm reiterated an outperform rating with a target price of 116 HKD [1]

Core Viewpoint - The report from Cinda Securities indicates that WuXi AppTec's TEDIS business is experiencing high growth, leading to an upward revision of the company's annual performance guidance [1] Financial Performance - In H1 2025, the company is expected to achieve a net profit attributable to shareholders of approximately 8.56 billion yuan, representing a year-on-year growth of 101.9% [1] - In Q2 2025, the adjusted net profit attributable to shareholders is projected to be 3.64 billion yuan, reflecting a year-on-year increase of 47.9% [1] Business Growth Drivers - The strong growth in the company's chemical business is primarily driven by the high demand in the TEDIS segment [1] - The demand for peptides and oligonucleotides remains robust, with a rich order backlog [1] - The company plans to increase its peptide solid-phase synthesis capacity to over 100,000 liters by the end of 2025, indicating a positive outlook for the next 1-2 years [1] Global Market Position - Approximately 85% of the company's revenue comes from overseas clients, establishing it as a fully globalized and competitive leader in the CRDMO sector [1] - Despite geopolitical concerns, the business growth from U.S. clients remains strong in H1 2025, alleviating market worries [1] - The global trend is expected to continue, with the company maintaining a solid position in the global supply chain [1]

药明康德（603259）(02359)公布，公司于2025年7月 29 日召开第三届董事会第二十三次会议，审议通 过了《关于调整回购股份价格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购A股股 份的回购股份价格上限由不超过 90.72 元/股(含)调整为不超过人民币 114.15 元/股，本次回购方案的其 他内容不变。 ...

医药医疗加快上行脚步！A股最大医疗ETF（512170）今日（2025年7月29日）刷新多项纪录：收涨2.45%报0.377元，收盘价创去年"924"以来次高！日线豪 取10连阳，刷新历史最长连阳纪录！全天成交11.52亿元，为近3个月次高。 制药板块同步活跃，国内首只药ETF（562050）盘中摸高2%，场内收涨1.68%，收盘价续创上市以来新高。百亿美元出海大单加持，核心权重股恒瑞医药继 昨日涨停后续涨2.84%，成交107.31亿元，跻身A股前三。 图片来源： 企业供图 药明康德交出"史上最强"半年报，CXO板块沸腾！医疗ETF（512170）覆盖的6只CXO龙头股集体上攻，药明康德涨7.72%，股价逼近100元，创3年新高！成 交90.14亿元，位列A股第7。此外，九洲药业涨停，昭衍新药午后触板。 中金公司指出，如今创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求起量以及一级创新药项目融资活跃度提升，内需CRO 有望受益。另一方面，中国企业成本与效率优势对海外客户具较强吸引力，外需CDMO订单趋势同样向好。 中泰证券提示，随着财报陆续披露，CXO、GLP-1等景气赛道表现亮眼。 ...

里昂发布研报称，将药明康德（02359）目标价从92.40港元上调至113.70港元；药明康德（603259.SH） 目标价从92.40元人民币上调至103.40元人民币，维持"跑赢大市"投资评级。 药明康德2025年第二季收入及经调整非国际财务报告准则净利润分别同比增长20%及48%，符合2025年 7月10日发布的盈利预告。公司将2025年持续经营业务收入增长指引，从10%至15%上调至13%至17%， 自由现金流指引从40亿元至50亿元人民币，上调到50亿元至60亿元人民币。考虑到上半年强劲表现，上 调后的收入指引并不显激进，并重申2025年经调整非国际财务报告准则净利润率将较2024年有所改善。 里昂相应上调药明康德2025至2027年全年收入及净利润预测，幅度分别为3%至4%及13%至17%，以反 映最新指引。 来源：新浪港股 ...

药明康德(02359)公布，公司于2025年7月 29 日召开第三届董事会第二十三次会议，审议通过了《关于 调整回购股份价格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购A股股份的回购股 份价格上限由不超过 90.72 元/股(含)调整为不超过人民币 114.15 元/股，本次回购方案的其他内容不 变。 ...

港交所披露数据显示，7月29日共615只港股被沽空，总沽空金额为288.22亿港元。其中沽空金额超1亿 港元的个股有74只，小米集团-W、腾讯控股、药明康德沽空金额位居前三，分别为22.09亿港元、9.55 亿港元、6.98亿港元。 （文章来源：第一财经） 从沽空比率来看，共32只个股沽空比率超30%，深圳高速公路股份、港铁公司、蔚来-SW位居前三，分 别为53.32%、51.83%、45.53%。 从沽空比率偏离幅度来看，共65只个股沽空比率偏离幅度超100%，中国旭阳集团、锅圈、微盟集团位 居前三，分别为403.05%、357.89%、345.55%。 ...